{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:38:11Z","timestamp":1789792691161,"version":"4.0.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020840","name":"NCRIS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020111","name":"Therapeutic Innovation Australia Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021954","name":"Tour de Cure Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.102989","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:36:44Z","timestamp":1781739404000},"page":"102989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemically delivered mRNA-LNPs transfect primary and secondary liver tumors"],"prefix":"10.1016","volume":"37","author":[{"given":"Laura J.","family":"Leighton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Jing","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachithrani U.","family":"Madugalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Victorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nissa L.","family":"Carrodus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim R.","family":"Bridle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney A.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris L.D.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danushka K.","family":"Wijesundara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell H.G.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-3175","authenticated-orcid":false,"given":"Seth W.","family":"Cheetham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102989_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omtn.2026.102989_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.20517\/mtod.2022.38","article-title":"Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms","volume":"3","author":"Lugari","year":"2023","journal-title":"Metab. Target Organ Damage"},{"key":"10.1016\/j.omtn.2026.102989_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s40471-019-00188-3","article-title":"The changing epidemiology of primary liver cancer","volume":"6","author":"Petrick","year":"2019","journal-title":"Curr. Epidemiol. Rep."},{"key":"10.1016\/j.omtn.2026.102989_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021535","article-title":"Treatment of liver cancer","volume":"5","author":"Liu","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.omtn.2026.102989_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/2050640616673516","article-title":"Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials","volume":"5","author":"Facciorusso","year":"2017","journal-title":"United Eur. Gastroenterol. J."},{"key":"10.1016\/j.omtn.2026.102989_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.17998\/jlc.2023.05.22","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association","volume":"23","author":"Cho","year":"2023","journal-title":"Journal of Liver Cancer"},{"key":"10.1016\/j.omtn.2026.102989_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","article-title":"Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma","volume":"100","author":"Sapir","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.omtn.2026.102989_bib8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2026.102989_bib9","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2026.102989_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","article-title":"Sorafenib: a review in hepatocellular carcinoma","volume":"12","author":"Keating","year":"2017","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.omtn.2026.102989_bib11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102989_bib12","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.omtn.2026.102989_bib13","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1055-9965.EPI-24-0626","article-title":"Hepatocellular carcinoma etiology drives survival outcomes: a population-based analysis","volume":"33","author":"Cranford","year":"2024","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.omtn.2026.102989_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.14740\/jocmr4902","article-title":"Prognostic scores and survival rates by etiology of hepatocellular carcinoma: a review","volume":"15","author":"Calderon-Martinez","year":"2023","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.omtn.2026.102989_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1463-1318.2010.02539.x","article-title":"Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series","volume":"14","author":"van der Pool","year":"2012","journal-title":"Colorectal Dis."},{"key":"10.1016\/j.omtn.2026.102989_bib16","first-page":"538","article-title":"Recurrent breast cancer: Presentation, diagnosis and treatment","volume":"20","author":"Jardines","year":"1993","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.omtn.2026.102989_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1572-0241.2000.01699.x","article-title":"A multispecialty approach to the diagnosis and management of pancreatic cancer","volume":"95","author":"Hawes","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.omtn.2026.102989_bib18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.omtn.2026.102989_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1634\/theoncologist.8-3-241","article-title":"A role for curative surgery in the treatment of selected patients with metastatic breast cancer","volume":"8","author":"Singletary","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.omtn.2026.102989_bib20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.21037\/tcr-20-3319","article-title":"Incidence and survival outcomes of secondary liver cancer: a Surveillance Epidemiology and End Results database analysis","volume":"10","author":"Wang","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.omtn.2026.102989_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/1754-9485.12163","article-title":"Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature","volume":"58","author":"Bester","year":"2014","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"10.1016\/j.omtn.2026.102989_bib22","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/S0959-8049(03)00553-7","article-title":"The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours","volume":"39","author":"Garcea","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omtn.2026.102989_bib23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5306\/wjco.v12.i9.725","article-title":"Metastatic disease to the liver: Locoregional therapy strategies and outcomes","volume":"12","author":"Zane","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2026.102989_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.102989_bib25","article-title":"Safety and adverse events related to COVID-19 mRNA vaccines; a systematic review","volume":"10","author":"SeyedAlinaghi","year":"2022","journal-title":"Archives of Academic Emergency Medicine"},{"key":"10.1016\/j.omtn.2026.102989_bib26","article-title":"Understanding nanomaterial\u2013liver interactions to facilitate the development of safer nanoapplications","volume":"34","author":"Li","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2026.102989_bib27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102989_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2026.102989_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41467-021-20903-3","article-title":"Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA","volume":"12","author":"Rizvi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102989_bib30","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.102989_bib31","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102989_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2026.102989_bib33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41586-024-07266-7","article-title":"Interim analyses of a first-in-human phase 1\/2 mRNA trial for propionic acidaemia","volume":"628","author":"Koeberl","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102989_bib34","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2021.08.011","article-title":"Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model","volume":"75","author":"Yang","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.omtn.2026.102989_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2024.11.010","article-title":"Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: A combined in vitro and preclinical perspective","volume":"377","author":"Binici","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102989_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1162\/153535004773861688","article-title":"Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models","volume":"3","author":"Troy","year":"2004","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.omtn.2026.102989_bib37","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"C. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2026.102989_bib38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","article-title":"Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects","volume":"20","author":"Kiaie","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2026.102989_bib39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","article-title":"Homozygous disruption of the murine Mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease","volume":"75","author":"Smit","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.102989_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","article-title":"Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"127","author":"Fickert","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2026.102989_bib41","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41597-023-02257-1","article-title":"GepLiver: an integrative liver expression atlas spanning developmental stages and liver disease phases","volume":"10","author":"Li","year":"2023","journal-title":"Sci. Data"},{"key":"10.1016\/j.omtn.2026.102989_bib42","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep4.1909","article-title":"FGF1 signaling modulates biliary injury and liver fibrosis in the Mdr2\u2212\/\u2212 mouse model of primary sclerosing cholangitis","volume":"6","author":"O\u2019Brien","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.omtn.2026.102989_bib43","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/protein\/12.12.1035","article-title":"Attenuation of green fluorescent protein half-life in mammalian cells","volume":"12","author":"Corish","year":"1999","journal-title":"Protein Eng."},{"key":"10.1016\/j.omtn.2026.102989_bib44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.omtn.2026.102989_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1978","article-title":"An overview of lipid constituents in lipid nanoparticle mRNA delivery systems","volume":"16","author":"Wu","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2026.102989_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113945","article-title":"Impact of ionizable lipid type on the pharmacokinetics and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection","volume":"384","author":"Ren","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102989_bib47","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","article-title":"Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration","volume":"4","author":"Carrasco","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtn.2026.102989_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102325","article-title":"The dynamic process of mRNA delivery by lipid nanoparticles in vivo","volume":"57","author":"Ma","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.omtn.2026.102989_bib49","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1021\/acsnano.0c10064","article-title":"Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles","volume":"15","author":"Sebastiani","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2026.102989_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0163-7827(00)00020-5","article-title":"The role of hepatocytes in the clearance of liposomes from the blood circulation","volume":"40","author":"Scherphof","year":"2001","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.omtn.2026.102989_bib51","doi-asserted-by":"crossref","first-page":"10025","DOI":"10.1021\/acs.nanolett.2c03741","article-title":"The extent to which lipid nanoparticles require apolipoprotein E and low-density lipoprotein receptor for delivery changes with ionizable lipid structure","volume":"22","author":"Paunovska","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2026.102989_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.102989_bib53","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1038\/s41467-025-60959-z","article-title":"Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol","volume":"16","author":"Johansson","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102989_bib54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","article-title":"Lipid-based nanoparticle technologies for liver targeting","volume":"154\u2013155","author":"B\u00f6ttger","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.102989_bib55","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.3748\/wjg.v20.i23.7312","article-title":"Pathogenesis of liver cirrhosis","volume":"20","author":"Zhou","year":"2014","journal-title":"World J. Gastroenterol.: WJG"},{"key":"10.1016\/j.omtn.2026.102989_bib56","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2319880121","article-title":"Curvature-mediated rapid extravasation and penetration of nanoparticles against interstitial fluid pressure for improved drug delivery","volume":"121","author":"Jiang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102989_bib57","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1038\/s41467-024-49332-8","article-title":"Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice","volume":"15","author":"Smith","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.102989_bib58","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41565-022-01122-3","article-title":"Enhancing CRISPR\/Cas gene editing through modulating cellular mechanical properties for cancer therapy","volume":"17","author":"Zhang","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2026.102989_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1565","article-title":"Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition","volume":"11","author":"Kong","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102989_bib60","article-title":"mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies","volume":"33","author":"Wang","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2026.102989_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s40425-018-0431-x","article-title":"Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma","volume":"6","author":"Lai","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.102989_bib62","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/1078-0432.CCR-14-0122","article-title":"Intratumor heterogeneity in hepatocellular carcinoma","volume":"21","author":"Friemel","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.102989_bib63","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtn.2026.102989_bib64","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102989_bib65","doi-asserted-by":"crossref","first-page":"8831","DOI":"10.1002\/ange.201003142","article-title":"A nanoparticle size series for in vivo fluorescence imaging","volume":"122","author":"Popovi\u0107","year":"2010","journal-title":"Angew. Chem."},{"key":"10.1016\/j.omtn.2026.102989_bib66","article-title":"Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2026.102989_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102520","article-title":"Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers","volume":"36","author":"Dietmair","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102989_bib68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/nat.2018.0734","article-title":"MicroRNAs enable mRNA therapeutics to selectively program cancer cells to self-destruct","volume":"28","author":"Jain","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2026.102989_bib69","article-title":"RNA-based therapies in hepatocellular carcinoma: state of the art and clinical perspectives","volume":"10","author":"Xing","year":"2024","journal-title":"Hepatoma Res."},{"key":"10.1016\/j.omtn.2026.102989_bib70","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omtn.2026.102989_bib71","article-title":"The design, manufacture and LNP formulation of mRNA for research use","volume":"1","author":"Leighton","year":"2025","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2026.102989_bib72","article-title":"mRNArchitect: sequence design of mRNA medicines","author":"Budzinska","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2026.102989_bib73","doi-asserted-by":"crossref","unstructured":"Ronneberger, O., Fischer, P. & Brox, T. in Medical Image Computing and Computer-Assisted Intervention\u2013MICCAI 2015: 18th International Conference, Munich, Germany, October 5-9, 2015, Proceedings, Part III 18. 234-241 (Springer).","DOI":"10.1007\/978-3-319-24574-4_28"},{"key":"10.1016\/j.omtn.2026.102989_bib74","article-title":"Pytorch: An imperative style, high-performance deep learning library","volume":"32","author":"Paszke","year":"2019","journal-title":"Adv. Neural Inf. Process. Syst."},{"key":"10.1016\/j.omtn.2026.102989_bib75","article-title":"Adam: A method for stochastic optimization","author":"Kingma","year":"2014","journal-title":"arXiv"},{"key":"10.1016\/j.omtn.2026.102989_bib76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtn.2026.102989_bib77","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omtn.2026.102989_bib78","article-title":"Degust: interactive RNA-seq analysis","volume":"4","author":"Powell","year":"2015","journal-title":"Drpowell\/Degust"},{"key":"10.1016\/j.omtn.2026.102989_bib79","doi-asserted-by":"crossref","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: customizable protein\u2013protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:02:48Z","timestamp":1788879768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126001605"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102989","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemically delivered mRNA-LNPs transfect primary and secondary liver tumors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102989"}}